{"schema_version":"secwatch.filing_event.v1","accession":"0001826667-25-000011","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.111685+00:00","generated_at":"2026-05-27T04:48:13.943874+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"TriSalus Life Sciences appoints two new directors, expands board to 11","bullets":["William Valle (Class I, term to 2027) and Gary Gordon (Class III, term to 2026) appointed Jan 29, 2025.","Valle receives $50k cash retainer plus $7.5k each for Audit and Compensation committees; initial option grant of 35k shares (3-yr vest).","Gordon receives $50k cash retainer plus $7.5k for Science & Technology Committee; same option grant structure as Valle.","No arrangements or understandings existed for selection of Valle or Gordon; no reportable transactions under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001826667-25-000011","json":"https://secwatch.observer/filing/0001826667-25-000011.json","markdown":"https://secwatch.observer/filing/0001826667-25-000011.md","text":"https://secwatch.observer/filing/0001826667-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/tlsi-20250129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:48:13.943874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3239bdca78","claim":"Gary Gordon was appointed as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9c464e99f1","claim":"William Valle was appointed as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}